Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Martin Hutchings; Carmelo Carlo-Stella; Franck Morschhauser; Lorenzo Falchi; Emmanuel Bachy; Guillaume Cartron; Cyrus Khan; Monica Tani; Joaquin Martinez-Lopez; Nancy L. Bartlett; Antonio Salar; Joshua Brody; Sirpa Leppä; Pauline Baumlin; Estefania Mulvihill; James Relf; Yuying Xie; Derrick Kaufman; Linda Lundberg; Michael Dickinson

doi:10.1016/S2152-2650(24)00811-5

$Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume$

Article de revue

Avec comité de lecture

Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Martin Hutchings, Carmelo Carlo-Stella, Franck Morschhauser, Lorenzo Falchi, Emmanuel Bachy, Guillaume Cartron, Cyrus Khan, Monica Tani, Joaquin Martinez-Lopez, Nancy L. Bartlett, …

Clinical lymphoma, myeloma and leukemia, Vol.24, pp.S215-S215

09/2024

DOI: https://doi.org/10.1016/S2152-2650(24)00811-5

Indicateurs

1 Consultations de la notice

Détails

Titre: Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume
Créateurs - sans rôle: Martin Hutchings - University of Copenhagen
Carmelo Carlo-Stella - Humanitas University
Franck Morschhauser - Hôpital Claude Huriez
Lorenzo Falchi - Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Emmanuel Bachy - Hôpital Lyon Sud
Guillaume Cartron - CHU de Montpellier, Montpellier, France
Cyrus Khan - Allegheny Health Network
Monica Tani - Ospedale Santa Maria delle Croci, Ravenna, Italy
Joaquin Martinez-Lopez - Department of Hematology, Hospital Universitario 12 de Octubre, Spanish National Cancer Research Center (CNIO), Complutense University Madrid, Madrid, Spain
Nancy L. Bartlett - Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA
Antonio Salar - Department of Hematology, Hospital del Mar, Passeig Maritim, Barcelona, Spain
Joshua Brody - Tisch Cancer Institute, New York, NY, USA
Sirpa Leppä - University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
Pauline Baumlin - F. Hoffmann-La Roche Ltd, Basel, Switzerland
Estefania Mulvihill - F. Hoffmann-La Roche Ltd, Basel, Switzerland
James Relf - Roche Products Ltd, Welwyn Garden City, United Kingdom
Yuying Xie - Hoffmann-La Roche Ltd, Mississauga, ON, Canada
Derrick Kaufman - Genentech, Inc., South San Francisco, CA, USA
Linda Lundberg - F. Hoffmann-La Roche Ltd, Basel, Switzerland
Michael Dickinson - The University of Melbourne
Détails de publication: Clinical lymphoma, myeloma and leukemia, Vol.24, pp.S215-S215
Éditeur: Elsevier Inc
Identifiants: 99139663009311
Unité académique: Institut de Génétique Moléculaire de Montpellier - IGMM
Langue: English
Type de ressource: Journal article